By the way all. The reason why jutawansenyap is so bitter here is because previously he bought at 32c and had to cut loss after that cos the price dropped. Padan muka hahahaha !!! So funny

@jutawansenyap when you open your mouth here, it really shows how dumb you are.. Dumber than a moron.. I feel embarrassed for you and I truly pity your mom who gave birth to you ... Even an artificial intelligence is smarter than you hahahaha

By the way your prlexus is gone case. Dead. Despite anticipation of good QR, the price is still like shit.

@UlarSawa Up to you it is your choice. However, as for me, i would not hesitate to get vaccinated with Sinopharm vaccine once it has been approved by NPRA as Sinopharm vaccine has already been tested in over 1 million people without any serious side effects... For me, Sinopharm vaccine is the safest choice of ALL apart from Sinovac vaccine as both vaccines are based on the tried and tested inactivated vaccine technology...

@UlarSawa One must understand that Taiwan is generally Anti-China and Pro-West. So they tend to be biased. Second of all, it is rather ignorant and unfair to paint ALL vaccines produced by China with the same brush.

Dr Noor Hisham has already warned the public not to be swayed by “fake” flyers being distributed by unknown quarters claiming that China vaccines are unreliable and has said the ministry is aware of flyers being distributed at mailboxes in Selangor making the claims against China. The information that has been published by this publication claiming that vaccines from China are ineffective are false. HE ALSO SAID THAT CHINA HAS PRODUCED MANY WORLD HEALTH ORGANISATION PRE-QUALIFIED VACCINES FOR INFLUENZA, POLIO, HEPATITIS A AND JAPANESE ENCEPHALITIS.

This is indeed true because Sinopharm has produced other WHO-prequalified vaccines before this.
-------------------------------------------------
The Health Ministry has warned the public not to be swayed by “fake” flyers being distributed by unknown quarters claiming that China vaccines are unreliable.

Health director-general Tan Sri Dr Noor Hisham Abdullah said the ministry is aware of flyers being distributed at mailboxes in Selangor making the claims against China.

“The information that has been published by this publication claiming that vaccines from China are ineffective are false," he said.

DR NOOR HISHAM ADDED THAT CHINA HAS PRODUCED MANY WORLD HEALTH ORGANISATION PRE-QUALIFIED VACCINES FOR INFLUENZA, POLIO, HEPATITIS A AND JAPANESE ENCEPHALITIS.

https://www.thestar.com.my/news/nation/2020/12/09/covid-19-don039t-be-swayed-by-flyers-slamming-chinese-vaccine-says-health-dg
-------------------------------------------------------
Chinese vaccines may gain inroads overseas before they win conditional approval in China, via EULs granted by other national regulators. Last month, a Sinopharm experimental vaccine became the first Chinese Covid-19 candidate to receive an overseas EUL, from the United Arab Emirates which approved it for its frontline health workers.

Other countries are also considering giving EULs to Chinese vaccines. Achmad Yurianto, director general of Disease Prevention and Control at Indonesia’s health ministry, has said his country plans to procure 18 million doses from China’s Sinovac, Sinopharm and CanSino, and could grant an EUL as early as November.

The World Health Organization(WHO) is holding pre-assessment meetings with Chinese vaccine developers after inviting expressions of interest from companies wishing to apply for a WHO EUL, but experts said the agency would first require efficacy data from Phase 3 clinical trials.

“There are only four Chinese pharmaceuticals that went through the World Health Organization prequalification procedures and to (have their vaccines) on the UN procurement list. That is mainly because Chinese manufacturers were not incentivised to get into the world market and, by their nature, vaccines are not high profit products.”
WHO prequalification for a vaccine means it has met the agency’s high regulatory requirements and is recommended for procurement by UN agencies and WHO member states.

Beijing has promised to provide Covid-19 vaccines to several dozen developing countries, following President Xi Jinping’s pledge in May to make its vaccines a global public good. After months of hesitation, China finally agreed to join Covax, the vaccine distribution mechanism led by the Bill Gates-backed alliance Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), and WHO.

Experts said the move would boost international confidence in Chinese vaccines and incorporate China’s vaccine industry into the world’s supply chain in the long term.

“THE BEAUTY FOR CHINA CONTRIBUTING TO COVAX IS THAT THE VACCINES HAVE TO BE WHO PRE-QUALIFIED, WHICH COMMITS THE CHINESE COMPANIES TO A STANDARD THAT IS ACTUALLY OVER THE INTERNATIONAL [GOOD MANUFACTURING PRACTICE] STANDARD THAT CHINA FOLLOWS,” SAID JEROME KIM, DIRECTOR GENERAL OF THE INTERNATIONAL VACCINE INSTITUTE FOUNDED BY THE UNITED NATIONS.

“If you have several major global health institutions – the WHO, CEPI, Gavi – all accepting the Chinese-made vaccines, procuring them and, for WHO, pre-qualifying them, it actually legitimises the Chinese-made vaccines,” said Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations.

SINOPHARM AND SINOVAC BOTH HAVE OTHER VACCINES PRE-QUALIFIED BY THE WHO. A SUBSIDIARY OF SINOPHARM WAS THE FIRST TO RECEIVE WHO PREQUALIFICATION FOR JAPANESE ENCEPHALITIS VACCINES AFTER YEARS OF SUPPORT FROM SEVERAL UN AGENCIES TO HELP IT MEET THE STANDARD. “THEY KNOW WHAT THE WHO WANTS,” KIM SAID, ADDING THAT CHINA WAS SUPPLYING 80 PER CENT OF THE JAPANESE ENCEPHALITIS VACCINES IN ASIA.

https://www.scmp.com/news/china/science/article/3107191/can-china-become-leading-producer-covid-19-vaccines

@UlarSawa Honestly, i will wait for Pfizer vaccine to be marketed for at least 6 months to 1 year as that vaccine is using a completely new technology that has never been approved for use globally prior to this. Hence, it would be prudent to wait until there is sufficient long term data to confirm it is truly safe to use.

However as for Sinopharm vaccine, no worries at all since it is using the same established vaccine technology as so many other vaccines worldwide that has been approved and marketed for many many years ie. inctivated vaccine technology. Examples of vaccines using this tried and tested inactivated vaccine technology are Hepatitis A, Flu, Polio, Rabies, Pertussis (Whooping cough) etc. etc. Furthermore, even the starting materials used to product Sinopharm Vacine are nothing new and have been used in the production of so many other established vaccines...

@Fong Kh Highly unlikely as the average private placement share price issued is 0.163. Issuance of private placement shares has just been completed today. Most likely, the share price will remain above this price. Otherwise, there will be no incentive for the 3rd party private investors to invest in the private placement shares when they can just purchase the shares from the open market. I am quite confident Kanger management will not allow that to occur.

@UlarSawa, Based on the link you shared above, the below statement can be found. Do not just read one line and ignore the rest of the article. You are just being ignorant...

--------------

"IT IS THUS IMPORTANT TO HAVE BOTH FORMS OF TREATMENT"

https://www.malaymail.com/news/singapore/2020/12/11/singapore-biotech-firm-tychan-starts-final-phase-of-covid-19-antibody-drug/1931058

@Fong Kh Yes you are right but it seems to have settled at 0.165... Lets see what happens next week...Only time can tell..

Thank god the number of anti-vaxxers in Malaysia are few.. Otherwise, we will not be able to achieve the target herd immunity of 70%...

@UlarSawa You sound like an anti-vaxxer here based on your illogical arguments...

@UlarSawa Of course vaccine alone is not enough. Vaccine is extremely important and will play a huge role in achieving herd immunity. Antibody is just to supplement vaccines because as you know vaccine efficacy is NOT 100%. Furthermore, NOT 100% of the population will opt for vaccination. Hence, despite vaccination, there will bound to be a small number of infections lingering amongst the population. Hence, antibody treatment still has a role and "fills that gap" to treat those unlucky few in the population that got infected.

If it werent for vaccines, polio would not have been able to be eradicated globally. You should thank vaccines for that...

@jutawansenyap Besides, Prlexus follows glove theme. Most of the institutions have already withdrawn from glove counters and moved on to recovery theme stocks. What is left in glove counters are mostly retailers...Its the end of glove and face mask counters for now.. The sentiment has died...

@UlarSawa. Vaccine is for prevention of infection whereas antibody is for cure once you have already been infected. 2 different things. As doctors always say, prevention is better than cure...

@jutawansenyap What makes you think that i bought at high price. Your assumptions make you look stupider than a moron. Your Prlexus is the biggest joke. Price is going down despite anticipation of good QR....

@18KHarmoni I highly doubt it will drop below 0.165...So no worries...

I have already made a promise to myself, if it drops below private placement price of 0.163, i will leave...0.165 is the lowest i am willing to accept based on that private placement price...However, if it remains above 0.165, i will keep for long term....

@joni No today close at 0.165....Keeping it real...

From the looks of it, Kanger will close at 0.165 today....As long as it doesn't drop below 0.165, i am contented for now...

I think institutions have already mostly withdrawn from glove counters and moved on the recovery theme counters leaving mostly retailers in the glove counters. Please correct me if am wrong...

I think institutions have already mostly withdrawn from glove counters and moved on the recovery theme counters leaving mostly retailers in the glove counters. Please correct me if am wrong...

I think institutions have already mostly withdrawn from glove counters and moved on the recovery theme counters leaving mostly retailers in the glove counters. Please correct me if am wrong...

I think institutions have already mostly withdrawn from glove counters and moved on the recovery theme counters leaving mostly retailers in the glove counters. Please correct me if am wrong...

I think institutions have already mostly withdrawn from glove counters and moved on the recovery theme counters leaving mostly retailers in the glove counters. Please correct me if am wrong...

With regards to COVAX which will be covering 10% of the Malaysian population, i believe the government will most probably select AstraZeneca vaccine as it is currently the only western vaccine available via COVAX. Even if Moderna vaccine joins COVAX later on, Malaysia will most certainly not select it as it is using the same vaccine technology/ platform as Pfizer vaccine ie mRNA vaccine

----------------------

AstraZeneca is the only one to have already struck a deal with COVAX, a global initiative to distribute COVID-19 vaccines equitably, including to low-income nations, according to data from the Duke Global Health Innovation Center.

COVAX has placed an order for 300 million doses from AstraZeneca. Meanwhile, Pfizer-BioNTech isn't part of the COVAX initiative, and Moderna is part of the COVAX project, but has not "quite aligned with them on how many doses and when those doses would be available," according to Axios.

https://www.businessinsider.com/how-covid-vaccines-compare-cost-astrazeneca-oxford-pfizer-biontech-moderna-2020-11

10% - Covax
20% - Pfizer

So 70% (herd immunity) - 10% - 20% = 40% of the Malaysian population still unaccounted for by the government...

@Kenie Malaysia has already signed the vaccine agreement with China. So like it or not, Chinese vaccine will be one of the choices that our government will be acquiring. However, as for now, Kanger will only be distributing the vaccines to private sector.

@Noobie123 Well said. Totally agree with you....

@bowman Hence, i doubt the company management will allow the share price to drop below average private placement price of 0.163. It would not make any sense to attract 3rd party investors when they can just buy the shares from the open market...

Prlexus follows glove theme. What are the chances of Prlexus price going up despite good QR result when the rest of the glove counters are down as institutions have generally already withdrawn from glove counters and moved on to recovery theme counters? Just keeping it real...Anyone care to speculate?

And i really hope that Kanger would be transparent enough to reveal the 3rd party investor(s) of the private placement shares soon...

I calculated the average price of private placement shares based on the number of shares issued and price at each tranche of private placement ie. 0.163. Hence,If it closes at 0.160, it is a bad sign.

Based on my limited knowledge of private placement, the company management by right should not allow the share price to drop below the average private placement share price because IF it were to happen, that would mean that there will be no incentive for the 3rd party investor to invest in the private placements shares when they can just purchase the share from the open market

Hence by logic, 0.165 would be a strong support. However, if i am am wrong and the price drops below 0.165, then it is a bad sign....

@lamy92 Thanks for your concern...

@UlarSawa Yes, i agree with you. Vaccine is just supplementary profit. The bamboo core business is the CASH COW that will generate most of the profits for the company.

@tinghn As i said, i am NOT part of the management so i do not know why they made that mistake. If you want to know further, go and visit Kanger officer in Malaysia and query them. Like i said, the ADDRESS IS THE SAME. If you think its fake then you can choose not to enter, your money your decision. I am here for the long term....

@Chua Joe Beng Regardless of vaccine or no vaccine, i am here for the long term due to the bamboo core business. So no worries for me...

@tinghn Sometimes chinese translation of the original name to english may not be accurate....Its not a big mistake.... I am NOT part of the management so dont ask me all these questions...You decide for yourself...

@Citadel12 Of course. This is because the agreement is contingent upon APPROVAL OF THE VACCINE BY NPRA. So DUH! Of course it will be cancelled if NRPA rejects the vaccine. However chances of rejection by NPRA are as good as chances of you being struck by a lightning. Its very low...

@tinghn The address matches....

----------
Found the official website of Sinopharm Group Hunan Changde Medical Co Ltd as follows but it is in Chinese. You can use google translate widget to view the webpage in English. The address stated is as follows and it matches the address stated in the COLLABORATION AGREEMENT WITH SINOPHARM GROUP HUNAN CHANGDE MEDICAL CO. LTD. document found in Bursa Malaysia website under Company Announcements :

No. 22, Longmei Street, Changde Economic and Technological Development Zone, Hunan Province (3rd Floor, Building 2, Area A, Small and Medium-sized Enterprise Park)

http://www.leosn.com/12

----------------------------
No. 22, 3rd Floor, Zone A, Tower 2, Long Mei Street, Changde Economic and Technological Development Changde, Hunan Province, PRC.

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=107445&name=EA_GA_ATTACHMENTS

@tinghn Its the same. Most probably a typo and they must have left out the work "Equipment".

@tinghn Sinopharm Hunan Changde is part of Sinopharm Group. The main reason why Kanger collaboration agreement is with Sinopharm Hunan Changde is because Sinopharm Hunan Changde is principally engaged in sale of medical supplies and equipment and the collaboration between Kanger and SInopharm Group is in the area of NOT JUST DISTRIBUTION OF COVID-19 VACCINE BUT DISTRIBUTION OF MEDICAL EQUIPMENTS AS WELL in Malaysia which are developed by Sinopharm Group of companies. There is always a reason for everything. Not sesuka hati,

@tinghn Its a subsidiary and part of Sinopharm Group

@UlarSawa Truth of the matter is we retailers here have no power to affect the price. Its the operators that can affect the price.. No matter what we talk about here be it bamboo or vaccine or both...

Reposting this...

---------------

Found the official website of Sinopharm Group Hunan Changde Medical Co Ltd as follows but it is in Chinese. You can use google translate widget to view the webpage in English. The address stated is as follows and it matches the address stated in the COLLABORATION AGREEMENT WITH SINOPHARM GROUP HUNAN CHANGDE MEDICAL CO. LTD. document found in Bursa Malaysia website under Company Announcements :

No. 22, Longmei Street, Changde Economic and Technological Development Zone, Hunan Province (3rd Floor, Building 2, Area A, Small and Medium-sized Enterprise Park)

http://www.leosn.com/12

----------------------------
No. 22, 3rd Floor, Zone A, Tower 2, Long Mei Street, Changde Economic and Technological Development Changde, Hunan Province, PRC.

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=107445&name=EA_GA_ATTACHMENTS

https://www.egypttoday.com/Article/1/95205/Egypt-receives-1st-batch-of-Sinopharm%E2%80%99s-COVID-19-vaccine-after

@tinghn Of course it is a subsidiary of Sinopharm. Even the logo is the same as Sinopharm group....

Found the official website of Sinopharm Group Hunan Changde Medical Co Ltd as follows but it is in Chinese. You can use google translate widget to view the webpage in English. The address stated is as follows and it matches the address stated in the COLLABORATION AGREEMENT WITH SINOPHARM GROUP HUNAN CHANGDE MEDICAL CO. LTD. document found in Bursa Malaysia website under Company Announcements :

No. 22, Longmei Street, Changde Economic and Technological Development Zone, Hunan Province (3rd Floor, Building 2, Area A, Small and Medium-sized Enterprise Park)

http://www.leosn.com/12

----------------------------
No. 22, 3rd Floor, Zone A, Tower 2, Long Mei Street, Changde Economic and Technological Development Changde, Hunan Province, PRC.

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=107445&name=EA_GA_ATTACHMENTS

Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.

“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.

“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.

SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.

https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/

Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.

“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.

“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.

SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.

https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/

Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.

“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.

“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.

SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.

https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/

Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.

“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.

“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.

SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.

https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/